Measured in a cell proliferation assay using M-07e human megakaryocytic leukemic cells. The EC50 for this effect is less than 0.3ng/ml.
Product Details
Product Details
Product Specification
Species | Human |
Synonyms | Thrombopoietin; C-mpl ligand (ML); Megakaryocyte colony-stimulating factor; Megakaryocyte growth and development factor (MGDF); Myeloproliferative leukemia virus oncogene ligand; |
Accession | P40225 |
Amino Acid Sequence | Ser22-Leu195, with C-terminal His Tag. |
Expression System | HEK293 |
Molecular Weight | 25-33 kDa (Reducing) |
Purity | >95% by SDS-PAGE, >90% by HPLC. |
Endotoxin | <0.1EU/μg |
Conjugation | Unconjugated |
Tag | His Tag |
Physical Appearance | Lyophilized Powder |
Storage Buffer | PBS, PH7.4 |
Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
Stability & Storage |
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. |
Reference | N Engl J Med. 1998 Sep 10;339(11):746-54. |
Background
Thrombopoietin (TPO) is a glycoprotein hormone that plays a crucial role in the regulation of platelet production and megakaryocyte differentiation. The human TPO protein consisting of 174 amino acids is primarily produced in the liver and kidneys. TPO acts by binding to its receptor, the c-Mpl receptor, which is expressed on the surface of hematopoietic stem cells and megakaryocytic progenitor cells. Upon binding, TPO activates signaling pathways that promote the proliferation and differentiation of megakaryocytes, leading to increased platelet production. TPO is essential for maintaining normal platelet levels in the blood and is a key regulator of thrombopoiesis.
Picture
Picture
Bioactivity

SDS-PAGE
2μg (R: reducing condition, N: non-reducing condition).
SEC-HPLC
>90% as determined by SEC-HPLC.
